EPO Issues Notice of Intent to Grant Alnylam Patent Covering siRNA Modifications
EPO Issues Notice of Intent to Grant Alnylam Patent Covering siRNA Modifications
Alnylam Pharmaceuticals said this week that the European Patent Office has issued the company a notification of its intent to grant the company a patent covering “compositions and methods for chemically modified siRNAs containing phosphorothioate and 2-O-alkyl modifications without any siRNA length restrictions.”